Tevogen (TVGN) Convertible Debt (2023)

Tevogen Bio Holdings' (TVGN) quarterly Convertible Debt came in at $14.2 million in Q4 2023.

Tevogen (TVGN) Convertible Debt (2023) Analysis & Trends

Tevogen Bio Holdings (TVGN) has 1 years of Convertible Debt data on file, last reported at $14.2 million in Q4 2023.

Quarterly Convertible Debt changed N/A year-over-year to $14.2 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $14.2 million (changed N/A YoY) and the FY2023 annual result came in at $14.2 million, changed N/A from the prior year.
Convertible Debt was little changed at $14.2 million in Q4 2023.
In the past five years, Convertible Debt ranged from a high of $14.2 million in Q4 2023 to a low of $14.2 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.69 Bn	131.84 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.54 Bn	78.54 Bn	3.93 Bn
3	Argenx Se	65.27 Bn	60.09 Bn	1.37 Bn
4	Moderna	59.41 Bn	54.27 Bn	52.00 Mn
5	BeOne Medicines	42.12 Bn	37.02 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.80 Bn	28.49 Bn	992.69 Mn
7	BioNTech SE	28.07 Bn	9.68 Bn	668.28 Mn
8	Insmed	27.55 Bn	26.39 Bn	358.27 Mn
9	Royalty Pharma	27.28 Bn	26.44 Bn	-
10	Tevogen	25.39 Mn	25.39 Mn	-

Download Data

Date	Value
Dec 31, 2023	14.22 Mn